112 related articles for article (PubMed ID: 29498403)
21. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
[TBL] [Abstract][Full Text] [Related]
23. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H
J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889
[TBL] [Abstract][Full Text] [Related]
24. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
[TBL] [Abstract][Full Text] [Related]
25. [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
Inoue K; Sugiura F; Kogita A; Yoshioka Y; Sukegawa Y; Hida J; Okuno K
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1276-9. PubMed ID: 25335716
[TBL] [Abstract][Full Text] [Related]
26. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
27. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
[TBL] [Abstract][Full Text] [Related]
28. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases.
Matsueda S; Komatsu N; Kusumoto K; Koga S; Yamada A; Kuromatsu R; Yamada S; Seki R; Yutani S; Shichijo S; Mine T; Fukuda T; Okamura T; Okuda S; Sata M; Honda J; Kaji M; Itoh K; Sasada T
Dev Comp Immunol; 2013 Sep; 41(1):68-76. PubMed ID: 23583523
[TBL] [Abstract][Full Text] [Related]
29. Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.
Corulli LR; Cecil DL; Gad E; Koehnlein M; Coveler AL; Childs JS; Lubet RA; Disis ML
Front Immunol; 2021; 12():729809. PubMed ID: 34526999
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
Okuno K; Sugiura F; Hida J; Tokoro T; Ishimaru E; Ueda K
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1906-8. PubMed ID: 22202234
[TBL] [Abstract][Full Text] [Related]
31. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
[TBL] [Abstract][Full Text] [Related]
32. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4.
Shingler WH; Chikoti P; Kingsman SM; Harrop R
Int Immunol; 2008 Aug; 20(8):1057-66. PubMed ID: 18567615
[TBL] [Abstract][Full Text] [Related]
33. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery.
Tanaka S; Harada M; Mine T; Noguchi M; Gohara R; Azuma K; Tamura M; Yamada A; Morinaga A; Nishikori M; Katagiri K; Itoh K; Yamana H; Hashimoto T
J Immunother; 2003; 26(4):357-66. PubMed ID: 12843798
[TBL] [Abstract][Full Text] [Related]
34. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
35. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
36. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
[TBL] [Abstract][Full Text] [Related]
38. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Yoshitake Y; Fukuma D; Yuno A; Hirayama M; Nakayama H; Tanaka T; Nagata M; Takamune Y; Kawahara K; Nakagawa Y; Yoshida R; Hirosue A; Ogi H; Hiraki A; Jono H; Hamada A; Yoshida K; Nishimura Y; Nakamura Y; Shinohara M
Clin Cancer Res; 2015 Jan; 21(2):312-21. PubMed ID: 25391695
[TBL] [Abstract][Full Text] [Related]
39. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
[TBL] [Abstract][Full Text] [Related]
40. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.
Noguchi M; Mine T; Komatsu N; Suekane S; Moriya F; Matsuoka K; Yutani S; Shichijo S; Yamada A; Toh U; Kawano K; Azuma K; Uemura H; Okuno K; Matsumoto K; Yanagimoto H; Yamanaka R; Oka M; Todo S; Sasada T; Itoh K
Cancer Biol Ther; 2010 Dec; 10(12):1266-79. PubMed ID: 20935522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
